HOPE Center Studies Evaluate the Economic Benefits of Conversion to Pegfilgrastim Biosimilars

(August 10, 2021)

College of Pharmacy clinical assistant professor ALI MCBRIDE, PharmD, MS, BCOP, FASHP, FAzPA and HOPE Center Investigator IVO ABRAHAM, PhD, RN recently co-authored two new studies. The first is published in the Journal of Medical Economics and titled Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: Cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment. Researchers estimated the cost-savings associated with switching from pegfilgrastim with on-body injector (brand name Neulasta Onpro) to the biosimilar pegfilgrastim-jmdb (brand name Fulphila) for preventing or treating chemotherapy-induced febrile neutropenia. Overall results showed that converting to the biosimilar was associated with significant cost-savings which could be allocated to provide more patients with additional prophylaxis or treatment.

Their second study was published in Leukemia Research and is titled Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma. In this study researchers developed a pharmacoeconomic simulation to assess the cost-efficiency of converting a panel of 20,000 patients at risk of chemotherapy-induced febrile neutropenia from pegfilgrastim to biosimilar pegfilgrastim-cbqv. They estimated how the savings could be used to provide access to R-CHOP therapy for non-Hodgkin lymphoma patients. The researchers determined that conversion to biosimilar therapy yielded savings up to $96,668,126 which allowed for the purchase of up to 13,999 doses of R-CHOP for the treatment of an additional 2,333 non-Hodgkin lymphoma patients at no increased cost to the payer. This simulation demonstrates the clinical-economic benefit of prophylaxis with biosimilar growth factor.